abstract |
The present invention relates to a new co-crystal compound of 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxazolidin-5-yl}methyl)-2-thiophenecarboxamide (rivaroxaban) and malonic acid: (see formula I) (see formula II), to processes for preparing it, to medicinal products comprising it, and to the use thereof in fighting diseases. |